Cantor Fitzgerald Investment Advisors L.P. Purchases 119,545 Shares of Novo Nordisk A/S $NVO

Key Points

• Cantor Fitzgerald Investment Advisors increased its Novo Nordisk position by 55.8% in the third quarter, purchasing 119,545 shares to bring its holdings to 333,620 shares valued at approximately $12.65 million.
• Other institutions also added to Novo Nordisk, while institutional investors and hedge funds collectively own 11.54% of the company.
• Novo’s outlook is mixed: promising CagriSema weight-loss results and an expanded share-buyback program support the stock, but competition, pricing pressure, and declining earnings estimates remain concerns. Analysts maintain an overall “Hold” rating, with shares recently trading near $39.10.

Cantor Fitzgerald Investment Advisors L.P. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 333,620 shares of the company's stock after purchasing an additional 119,545 shares during the period. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Novo Nordisk A/S were worth $12,648,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Novo Nordisk A/S by 2,414.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company's stock valued at $14,280,000 after acquiring an additional 286,034 shares during the last quarter. Trust Co. of Vermont purchased a new stake in Novo Nordisk A/S during the second quarter worth approximately $1,250,000. Pine Valley Investments Ltd Liability Co acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $2,324,000. Myriad Asset Management Advisors LLC acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $1,846,000. Finally, Smith Chas P & Associates PA Cpas boosted its holdings in Novo Nordisk A/S by 18.5% in the second quarter. Smith Chas P & Associates PA Cpas now owns 950,151 shares of the company's stock valued at $45,550,000 after purchasing an additional 148,565 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced an average 25% reduction in body weight after 68 weeks among women with obesity or overweight in a late-stage analysis. The result strengthens the drug’s potential as a successor to Wegovy and could improve Novo’s long-term position in the expanding obesity-treatment market. Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
• Positive Sentiment: The CagriSema data prompted a recent rally as investors viewed the treatment’s efficacy as a potential catalyst for renewed growth. Regulatory submissions and further clinical progress could provide additional upside, although approval is not yet guaranteed. Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
• Positive Sentiment: Novo expanded its 2026 share buyback, increasing its treasury-share stake to 1.2%. The program signals management’s confidence and may support earnings per share by reducing the number of shares outstanding. Novo Nordisk expands 2026 share buyback
• Neutral Sentiment: Novo remains a major player in diabetes and obesity treatments, with additional pipeline projects and partnerships offering potential growth over the next decade. However, those benefits depend on successful trials, regulatory approvals, manufacturing investment, and commercialization. Where Will Novo Stock Be in 10 Years?
• Negative Sentiment: Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates. These concerns help explain why the stock remains under pressure despite the promising CagriSema results. How Investors May Respond To Novo Nordisk Obesity Drug Competition

Analyst Ratings Changes

Several brokerages have recently issued reports on NVO. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Barclays reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 7th. DZ Bank reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Jefferies Financial Group reissued a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Five analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $59.44.

Novo Nordisk A/S Stock Down 0.6%

NVO stock opened at $39.10 on Thursday. The company has a fifty day moving average price of $42.21 and a 200 day moving average price of $44.01. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a market cap of $174.58 billion, a price-to-earnings ratio of 9.79, a price-to-earnings-growth ratio of 1.34 and a beta of 0.76. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Sell-side analysts expect that Novo Nordisk A/S will post 3.42 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. This is a negative change from Novo Nordisk A/S's previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S's payout ratio is currently 20.05%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.